奥洛兹美医疗 HALO 深 沪
已收盘 12-12 16:00:00 美东时间
62.21
+0.310
+0.50%
华盛通- 最 高62.635
- 今 开61.93
- 成交量 562.90万股
- 最 低 61.28
- 昨 收 61.90
- 总市值 72.79亿
- 52周最高 79.50
- 市盈率 静 18.13
- 换手率 4.81%
- 52周最低 46.26
- 委 比 69.92%
- 总股本 1.17亿
- 历史最高 79.50
- 量 比 2.25
- 振 幅 2.19%
- 历史最低 3.86
- 每 手 1
- 风险率 7.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Halozyme Approves Stock Grant for CEO Incentive
An update from Halozyme ( ($HALO) ) is now available. On December 4, 2025, Halo...
12-10 06:17
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
12-09 05:05
Halozyme Therapeutics Granted Preliminary Injunction From German Court Against Merck's Keytruda
Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in
12-05 02:30
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $90 price target.
11-28 20:11
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $56
Goldman Sachs analyst Graig Suvannavejh maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $54 to $56.
11-19 01:56
Halozyme Therapeutics Announces Johnson & Johnson Gets US FDA's Approval Of New Indication For DARZALEX Faspro Co-formulated With ENHANZE To Treat Smoldering Multiple Myeloma
Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and
11-07 21:31
Halozyme Therapeutics prices $1.3 billion convertible notes
Halozyme Therapeutics (HALO) priced $650 million aggregate principal amount of 0% convertible senior notes due 2031 and $650 million aggregate principal amount of 0.875% convertible senior notes due...
11-07 13:57
